EVOGENE LTD (EVGN) Stock Price, Forecast & Analysis

NASDAQ:EVGN • IL0011050551

0.8207 USD
-0.07 (-7.54%)
At close: Feb 20, 2026
0.83 USD
+0.01 (+1.13%)
After Hours: 2/20/2026, 8:00:01 PM

EVGN Key Statistics, Chart & Performance

Key Statistics
Market Cap7.16M
Revenue(TTM)5.15M
Net Income(TTM)-2.75M
Shares8.72M
Float8.63M
52 Week High2.42
52 Week Low0.81
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.5
PEN/A
Fwd PEN/A
Earnings (Next)03-05
IPO2007-06-11
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
EVGN short term performance overview.The bars show the price performance of EVGN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

EVGN long term performance overview.The bars show the price performance of EVGN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of EVGN is 0.8207 USD. In the past month the price decreased by -20.32%. In the past year, price decreased by -42.08%.

EVOGENE LTD / EVGN Daily stock chart

EVGN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
EVGN Full Technical Analysis Report

EVGN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EVGN. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EVGN Full Fundamental Analysis Report

EVGN Financial Highlights

Over the last trailing twelve months EVGN reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 88.81% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -10.54%
ROE -240.72%
Debt/Equity 1.62
Chartmill High Growth Momentum
EPS Q2Q%133.59%
Sales Q2Q%-82.63%
EPS 1Y (TTM)88.81%
Revenue 1Y (TTM)-31.13%
EVGN financials

EVGN Forecast & Estimates

7 analysts have analysed EVGN and the average price target is 2.55 USD. This implies a price increase of 210.71% is expected in the next year compared to the current price of 0.8207.

For the next year, analysts expect an EPS growth of 79.67% and a revenue growth -62.81% for EVGN


Analysts
Analysts82.86
Price Target2.55 (210.71%)
EPS Next Y79.67%
Revenue Next Year-62.81%
EVGN Analyst EstimatesEVGN Analyst Ratings

EVGN Ownership

Ownership
Inst Owners1.93%
Ins Owners0.96%
Short Float %0.87%
Short Ratio0.14
EVGN Ownership

EVGN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.48396.512B
AMGN AMGEN INC16.63202.199B
GILD GILEAD SCIENCES INC16.97187.492B
VRTX VERTEX PHARMACEUTICALS INC23.39119.063B
REGN REGENERON PHARMACEUTICALS16.7882.713B
ALNY ALNYLAM PHARMACEUTICALS INC50.1944.834B
INSM INSMED INC N/A34.336B
NTRA NATERA INC N/A30.104B
BIIB BIOGEN INC12.6228.19B
UTHR UNITED THERAPEUTICS CORP16.0620.691B

About EVGN

Company Profile

EVGN logo image Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Company Info

EVOGENE LTD

13 Gad Feinstein Street, Park Rehovot

Rehovot 7414002 IL

CEO: Ofer Haviv

Employees: 117

EVGN Company Website

EVGN Investor Relations

Phone: 97289311900

EVOGENE LTD / EVGN FAQ

Can you describe the business of EVOGENE LTD?

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.


Can you provide the latest stock price for EVOGENE LTD?

The current stock price of EVGN is 0.8207 USD. The price decreased by -7.54% in the last trading session.


Does EVOGENE LTD pay dividends?

EVGN does not pay a dividend.


How is the ChartMill rating for EVOGENE LTD?

EVGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the employee count for EVGN stock?

EVOGENE LTD (EVGN) currently has 117 employees.


When does EVOGENE LTD (EVGN) report earnings?

EVOGENE LTD (EVGN) will report earnings on 2026-03-05, before the market open.


Can you provide the ownership details for EVGN stock?

You can find the ownership structure of EVOGENE LTD (EVGN) on the Ownership tab.